All News
🟢 MSCI is trading 3.22% up on November 5, 2026, amid financial-sector strength after midterm results
MSCI is trading at $24.66, up +3.22%, with the gain consistent with financial-sector strength after U.S. midterm results eased political uncertainty. - No...
Wendy's Adopts Stockholder Rights Plan After Rejecting $7.35/Share Takeover Proposal
The Wendy's Company has adopted a limited-duration stockholder rights plan, commonly known as a "poison pill," in response to an unsolicited, non-binding...
🟢 Regional Banks ETF (DPST) is trading 2.71% up in pre-market as election uncertainty eased
DPST is trading 2.71% higher pre-market after Wednesday’s 5.20% rise, as election uncertainty eased and investors rotated into banks. - Banks led the...
🟢 Commerce.com is trading 10% up in pre-market after Q3 revenue and adjusted profitability beat expectations
Commerce.com is trading at $3.79, up +9.89% in pre-market, after its Q3 report beat expectations for revenue and adjusted profitability. - The November 5...
Lincoln International reports record third quarter 2026 revenue of $293.7M and $0.46 adjusted EPS beat
Lincoln International reported record results for the third quarter of 2026, with revenue of $293.7 million increasing 57% year-over-year. Adjusted diluted EPS...
Shutterstock's third quarter 2026 revenue of $174M missed estimates amid a massive goodwill impairment
Shutterstock reported a sharp revenue contraction and a substantial net loss for the third quarter 2026. Revenue fell 33% year-over-year to $173.9 million,...
🟢 Appian is trading 5% up in pre-market after third-quarter revenue rose 25% year over year
Appian is trading at $52.25, up 4.88%, after third-quarter revenue rose 25% year over year. - Third-quarter revenue was $234.6 million; cloud subscription...
Verisk beats third quarter 2026 estimates with 7.4% organic revenue growth and margin expansion
Verisk reported third quarter 2026 results that exceeded analyst estimates on both the top and bottom lines. Growth was primarily fueled by strong subscription...
🔴 ARMG is trading 11.1% down as a ARM-linked ETF
ARMG is trading at $7.65, down 11.1% from a comparison close of $8.61 during pre-market. This product targets about 2x daily exposure to ARM; no separate...
Aclaris Therapeutics narrower third quarter 2026 loss beat estimates as cash runway extends to 2029
Aclaris Therapeutics reported a narrower-than-expected net loss for the third quarter of 2026, driven by disciplined research spending and a gain from the...
BlackSky's Breakout Quarter Rewrites the Growth Story — But Can a Satellite Spy Firm Sustain 118% Revenue Surges?
Shares of BlackSky Technology surged 16.9% to $19.60 after the satellite intelligence company posted third-quarter results that blew past Wall Street...
Shift4 Misses on Revenue and Cuts Guidance Again — How Many Resets Can Investors Stomach Before the Growth Story Unravels?
Shares of Shift4 Payments cratered 16.6% to $37.39 in pre-market trading Thursday after the payments processor reported Q3 net revenue of $648 million, missing...
Ceragon Beats on Every Line and Narrows Its 2026 Outlook — But Can a $200 Million Company Sustain This Momentum?
Shares of Ceragon Networks jumped 9.5% to $2.19 in pre-market trading on November 5 after the Israeli wireless-equipment maker posted third-quarter results...
🟢 YPF is trading 6% up in pre-market
YPF is trading at $44.00, up 5.74% in pre-market, with no verified company-specific catalyst identified. - No verified source explicitly links a November 5...
🟢 XLC is trading 1.85% up in pre-market with no clear catalyst identified
XLC is trading at $106.90, up +1.85%, in pre-market, with no clear XLC-specific catalyst for the November 5 move identified in available news. - A market...
🔴 Vistance Networks (VISN) trading 7.45% down in pre-market after Q3 revenue miss and reduced full-year outlook
Vistance Networks (VISN) is trading 7.45% down at $5.96 in pre-market amid a third-quarter revenue miss and lower full-year outlook. - The company's November...
Akebia Therapeutics third quarter 2026 revenue misses as Vafseo inventory adjustments offset patient growth
Akebia reported third quarter 2026 results that fell short of analyst estimates on both top and bottom lines, as a steep decline in Auryxia sales more than...
Xeris Biopharma's third quarter 2026 revenue of $107M beat estimates by 77% as Recorlev sales surged
Xeris Biopharma reported third quarter 2026 financial results that significantly exceeded consensus expectations, driven by a 93% year-over-year increase in...
Kimbell Royalty Partners third quarter 2026 revenue of $86.3M misses estimates despite record production levels
Kimbell Royalty Partners reported a record operational quarter, although headline financial figures fell short of analyst consensus estimates. The Partnership...
ConocoPhillips beats third quarter 2026 estimates with 2.3 million BOED production and dividend hike
ConocoPhillips delivered third quarter 2026 results that surpassed analyst expectations on both the top and bottom lines. Financial performance was bolstered...